← All deals

INFLAMMATIX, INC.

BiotechnologyBiotechnologyDiagnosticsMolecular Diagnostics
πŸ“ Sunnyvale, CA, United Statesβ€’ Founded 2016
StreetZero Signal 81
Be the first to signal interest

About INFLAMMATIX, INC.

Inflammatix is a molecular diagnostics company developing point-of-care tests that profile a person’s immune response to quickly determine bacterial and viral infections and help curb antimicrobial resistance. Its Myrna system and InSep test target sepsis and acute infections, with the ViraBac EZ fingerstick test also in development. The company is headquartered in Sunnyvale, California and was founded in 2016.

LATEST FUNDINGPrivate Placement
$47.4M
Announced 2026-11-19
TOTAL RAISED$200M+
πŸ”’

Unlock the full deal profile

Create a free account to see investors, key highlights, news, company details and the AI analysis for INFLAMMATIX, INC..

Free plan includes 3 full deal profiles every month.

Key highlights

  • Secured $102M in Series D financing led by D1 Capital Partners to advance commercialization.
  • Closed $57M Series E round in September 2024 led by Khosla Ventures and Think.Health.
  • Total private capital raised exceeds $200 million over eight years.
  • Developing Myrna system and InSep test for sepsis and acute infections with FDA submission underway.
  • Backed by multiple institutional investors including Northpond Ventures and OSF Healthcare Ventures.

Source document & SEC filing

The source SEC filing and the cached document are available to members only. Sign in to view and download them.

Sign in to view the filing Create free account